12:09 IST
NSE
Fund Raise
Beta Drugs Fund Raise
Beta Drugs Limited allotted 6,65,314 equity shares upon conversion of CCDs on May 25, 2026. This increases the company's paid-up share capital to ₹11.09 Crore.
Beta Drugs Ltd
- Share price
- ₹1,991.00
- Market cap
- ₹2,207 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 48.4×Sector 47.4×
- Promoter holding
- 59.10%-5.53% QoQ
- FII holding
- 1.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Fund Raise 5Earnings Call 3Board Meeting Date 3Price Movement Clarification 2Other Announcement 2Financial Results 2Board Meeting Outcome 2Share Pledge 1Results Correction 1Regulatory Approval 1Management Change 1Capital Structure Change 1Business Update 1Annual General Meeting 1Acquisition 1
Time
5 announcements with these filters
16:12 IST
NSE
Fund Raise
Beta Drugs Fund Raise of ₹117 Cr
Beta Drugs Limited reported utilization of ₹117.01 Crore raised through preferential issues. The Monitoring Agency confirms funds were deployed for subsidiary upgradation and R&D.
- Value
- ₹117.0 Cr
14:01 IST
NSE
Fund Raise
Beta Drugs Fund Raise of ₹4.86 Cr
Beta Drugs Limited has allotted 2,83,668 equity shares via a preferential issue at ₹1,712.49 per share, raising approximately ₹4.86 Crore. The shares were issued to 33 investors on a pari-passu basis, increasing the company's paid-up share capital to ₹10.42 Crore.
- Value
- ₹4.86 Cr
13:59 IST
NSE
Fund Raise
Beta Drugs Fund Raise of ₹48.58 Cr
Beta Drugs Limited allotted 2,83,668 equity shares at ₹1712.49 each, totaling ₹48.58 Crore. This issuance is part of the consideration for the acquisition of Nivian Lifesciences Private Limited, expanding the company's equity base.
- Value
- ₹48.58 Cr
10:24 IST
NSE
Fund Raise
Beta Drugs Fund Raise
Beta Drugs Limited provided a shareholding clarification regarding its proposed preferential issue. Following the issuance of equity shares and conversion of CCDs, the total share capital will increase to 1,10,85,872 shares, with promoter holding adjusting from 64.63% to 59.10%.